Ryvu Therapeutics and Selvita originated in 2007, a time when drug
discovery in Poland was still not pursued by industrial enterprises. For many years,
both entities operated one company and were known under a common name Selvita
S.A., combining their efforts on both innovative small-molecule therapeutics for
oncology and expertise in Contract Research Services (CRO). Following more than
a decade of such a hybrid business model, Selvita established a strong position in
the field of drug discovery and built trust among partners, clients, and investors
globally. This encouraged the leaders of the company to separate the two divisions
into fully autonomous units, which in fact, had already been operating quite
independently and both were successful in diverse areas of drug discovery
activities. At the beginning of October 2019, two new companies were established
and both parts were given independence and more opportunities for growth.
Discovery and development engine was named as Ryvu Therapeutics, and the CRO
part of the company remained with the name Selvita. To reach this stage, both the
divisions went through an interesting journey together, supporting and
strengthening each other for the benefit of both.
A robust R&D project portfolio optimization model for pharmaceutical contract research organizations
